MONOCLONAL ANTIBODY AGAINST APOLIPOPROTEIN A-I

(19)

(11)

EP 1 142 996 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	published in accordance with Art. 158(3) EPC

(48)	Corrigendum issued on:
	30.01.2002 Bulletin 2002/05

(43)	Date of publication:
	10.10.2001 Bulletin 2001/41

(21)	Application number: 99959883.2

(22)	Date of filing: 17.12.1999

(51)	International Patent Classification (IPC)⁷: C12N 15/08, C07K 16/18, C12N 5/12, C12P 21/08, G01N 33/53, G01N 33/577

(86)	International application number:
	PCT/JP9907/106

(87)	International publication number:
	WO 0037/632 (29.06.2000 Gazette 2000/26)

(84)	Designated Contracting States:
	DE FR GB

(30)

Priority:

22.12.1998 JP 36429598

(71)	Applicant: DAIICHI PURE CHEMICALS CO. LTD.
	Chuo-ku Tokyo 103-0027 (JP)

(72)	Inventors:
	MIYAZAKI, Osamu Daiichi Pure Chemicals Co., Ltd. Naka-gun, Ibaraki 319-1112 (JP) FUKAMACHI, Isamu Daiichi Pure Chemicals Co., Ltd. Naka-gun, Ibaraki 319-1112 (JP)

(74)	Representative: Hartz, Nikolai F., Dr. et al
	Wächtershäuser & Hartz, Patentanwälte, Tal 29 80331 München 80331 München (DE)

(54)	MONOCLONAL ANTIBODY AGAINST APOLIPOPROTEIN A-I

(57) The present invention is drawn to a monoclonal antibody reacting specfically with (1) apoA-I occurring in HDL containing no apoA-II and having a molecular weight of 150,000 or less; and (2) apoA-I not binding to a lipid; a hybridoma producing this antibody; a method of immunologically assaying apoA-I characterized by reacting the antibody with a specimen; and an assay reagent for apoA-I which contains the antibody. The invention realizes measurement of a specific apoA-I, which provides a novel index of lipid metabolism disorder, etc.